European Approval as a class IIa medical device:
APROTECOL® is intended to the treatment of meteorism, aerophagy and flatulent colics in infants, children and adults. The film-forming agent contained in APROTECOL® contributes to reduce the interaction of intestinal pathogens with the mucus membrane and their subsequent proliferation, thus preventing the rise of altered biologic responses which may provoke the increase of the gas content in the intestine. The presence of tyndallized lactobacillus reuterii and Bifidobacterium Brevis contributes to the prevention of pathogenic bacterial invasion.
APROTECOL® is available in drops.